Professor Yehuda G Assaraf Promoted to Co-Editor-in-Chief of Cancer Drug Resistance Journal

We are delighted to announce the promotion of Professor Yehuda Gerard Assaraf to the position of Co-Editor-in-Chief of Cancer Drug Resistance journal, effective February 21, 2024. Professor Assaraf, formerly the Associate Editor of the journal, has been recognized as a top 1% highly cited researcher in the field of Pharmacology and Toxicology by Clarivate for three consecutive years (2021-2023). With prior experience as the former Editor-in-Chief of Drug Resistance Updates, Professor Assaraf brings a wealth of expertise, experience, and a distinguished academic background, contributing significantly to the advancement of cancer research and understanding of drug resistance mechanisms.

In 1982, Professor Assaraf graduated with distinction, earning a Bachelor's degree in Biology from the Hebrew University of Jerusalem. He went on to obtain his Ph.D. in Molecular Biology and Biochemistry from the Hebrew University-Hadassah Medical School in 1987, under the supervision of Professor Uriel Bachrach and Professor Dan T. Spira.

Throughout his illustrious career, Professor Assaraf has held various pivotal positions in academia. Notably, he served as a Visiting Professor at renowned institutions such as the Cancer Center of Amsterdam/VU-Institute of Cancer and Immunology (CCA/V-ICI) from 2011 to 2017, and during his tenure as a Visiting Professor at the Cancer Center of Amsterdam, he was awarded the prestigious KNAW Award by the Royal Netherlands Academy of Arts and Sciences. Additionally, he served as the Dean of the Faculty of Biology at the Technion-Israel Institute of Technology from 2012 to 2018.

From 2015 to 2022, Professor Yehuda Gerard Assaraf served as the Editor-in-Chief of Drug Resistance Updates. Under his leadership, the journal's impact factor increased from 7.95 to 24.3 over the span of 7 years. In 2023, Professor Assaraf assumed the role of Adjunct Professor at the Faculty of Health Sciences, University of Macau.

Professor Assaraf's primary research focus has been on elucidating the molecular mechanisms underlying drug resistance in malignant cell lines and cancer patients. His contributions to this field have been recognized with numerous prestigious awards, including the Novartis Pharma Research Award in 2005 and the Hilda and Hershel Rich Technion Innovation Award in 2010 and 2014.

Professor Assaraf's significant contributions to understanding the molecular mechanisms of drug resistance in cancer and his dedication to academic excellence make him a valuable addition to the leadership of the Cancer Drug Resistance journal.

We are confident that under the joint leadership of Professor Godefridus J. Peters and Professor Yehuda G. Assaraf, along with the support of the Editorial Board members, authors, and readers, our journal will continue to serve as a premier international platform for disseminating cutting-edge research in the field of cancer drug resistance.

Editor: Louise Pan
Language Editor: Catherine Yang
Production Editor: Yan Zhang
Respectfully Submitted by the Editorial Office of Cancer Drug Resistance